COMP <GO>
ACTU vs QNRX // EV/EBITDA & P/E VALUATION
Actuate Therapeutics Inc. (NASDAQ) VS. Quoin Pharmaceuticals Ltd. (NASDAQ) • 15-METRIC TALLY: ACTU 2
— QNRX 1
■ METRIC PARITY
LAST: $0.37 (-3.21%) • MKT CAP: $20.4M
valuation
—
LAST: $4.15 (+0.97%) • MKT CAP: $19.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACTU VS. QNRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACTU | QNRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | ACTU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.1 | 49.3 | -17.21 | QNRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $20.4M | $19.9M | $467.5K | ACTU | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACTU REV | QNRX REV | ACTU GROSS % | QNRX GROSS % | ACTU FCF | QNRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$19.2M | -$13.5M |
| FY 2024 | $0 | $0 | — | — | -$21.8M | -$7.9M |
| FY 2023 | $0 | $0 | — | — | -$21.6M | -$7.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACTU // BETA —
QNRX // BETA —